EA200000013A1 - Комбинационная терапия, включающая в себя амлодипин и статиновое соединение - Google Patents
Комбинационная терапия, включающая в себя амлодипин и статиновое соединениеInfo
- Publication number
- EA200000013A1 EA200000013A1 EA200000013A EA200000013A EA200000013A1 EA 200000013 A1 EA200000013 A1 EA 200000013A1 EA 200000013 A EA200000013 A EA 200000013A EA 200000013 A EA200000013 A EA 200000013A EA 200000013 A1 EA200000013 A1 EA 200000013A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- pharmaceutically acceptable
- combinations
- amlodipine
- statin
- connection
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
Abstract
Это изобретение относится к фармацевтическим комбинациям амлодипина или его фармацевтически приемлемой соли присоединения кислоты и статинов или их фармацевтически приемлемых солей к наборам, включающим в себя такие комбинации, и к способам применения таких комбинаций для лечения субъектов, страдающих стенокардией, атеросклерозом, сочетанием гипертензии и гиперлипидемии, и для лечения субъектов, которые имеют симптомы риска нарушения сердечной деятельности, в том числе людей. Это изобретение также относится к аддитивным и синергическим комбинациям амлодипина или его фармацевтически приемлемой соли присоединения кислоты и статинов или их фармацевтически приемлемых солей, которые полезны при лечении субъектов, страдающих стенокардией, атеросклерозом, сочетанием гипертензии и гиперлипидемии, и субъектов, которые имеют симптомы риска нарушения сердечной деятельности, в том числе людей.Международная заявка была опубликована вместе с отчетом о международном поиске.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5755597P | 1997-08-29 | 1997-08-29 | |
PCT/IB1998/001220 WO1999011263A1 (en) | 1997-08-29 | 1998-08-10 | Combination therapy comprising amlodipine and a statin compound |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200000013A1 true EA200000013A1 (ru) | 2000-08-28 |
EA002705B1 EA002705B1 (ru) | 2002-08-29 |
Family
ID=22011309
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200000013A EA002705B1 (ru) | 1997-08-29 | 1998-08-10 | Комбинационная терапия, включающая в себя амлодипин и статиновое соединение |
Country Status (37)
Country | Link |
---|---|
US (1) | US20020025981A1 (ru) |
EP (1) | EP1003507A1 (ru) |
JP (1) | JP2001514224A (ru) |
KR (1) | KR20010022385A (ru) |
CN (1) | CN1117566C (ru) |
AP (1) | AP1207A (ru) |
AR (1) | AR017514A1 (ru) |
AU (1) | AU744982B2 (ru) |
BG (1) | BG104076A (ru) |
BR (1) | BR9811558A (ru) |
CA (1) | CA2296726C (ru) |
CO (1) | CO4970726A1 (ru) |
DZ (1) | DZ2600A1 (ru) |
EA (1) | EA002705B1 (ru) |
GT (1) | GT199800134A (ru) |
HK (1) | HK1029530A1 (ru) |
HN (1) | HN1998000124A (ru) |
HR (1) | HRP980475A2 (ru) |
HU (1) | HUP0003103A3 (ru) |
ID (1) | ID24275A (ru) |
IL (2) | IL133957A0 (ru) |
IS (1) | IS5345A (ru) |
MA (1) | MA26539A1 (ru) |
NO (1) | NO20000999D0 (ru) |
NZ (1) | NZ502283A (ru) |
OA (1) | OA11289A (ru) |
PA (1) | PA8457201A1 (ru) |
PE (1) | PE106999A1 (ru) |
PL (1) | PL339088A1 (ru) |
SA (1) | SA98190432A (ru) |
SK (1) | SK1392000A3 (ru) |
TN (1) | TNSN98158A1 (ru) |
TR (1) | TR200000562T2 (ru) |
UY (1) | UY25159A1 (ru) |
WO (1) | WO1999011263A1 (ru) |
YU (1) | YU2700A (ru) |
ZA (1) | ZA987843B (ru) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1076091A1 (en) * | 1999-08-09 | 2001-02-14 | Universite Catholique De Louvain | Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds |
DE19944803A1 (de) * | 1999-09-20 | 2001-03-29 | Bayer Ag | Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln |
EP1314425A4 (en) * | 2000-08-30 | 2004-06-02 | Sankyo Co | MEDICINAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE |
AUPR255401A0 (en) * | 2001-01-16 | 2001-02-08 | Novogen Research Pty Ltd | Regulation of lipids and/or bone density and compositions therefor |
US20030114497A1 (en) * | 2001-07-31 | 2003-06-19 | Laman Alani | Pharmaceutical compositions of amlodipine and atorvastatin |
NL1019882C2 (nl) * | 2002-02-01 | 2003-08-04 | Synthon Licensing | Amlodipine vrije base. |
US20040053842A1 (en) * | 2002-07-02 | 2004-03-18 | Pfizer Inc. | Methods of treatment with CETP inhibitors and antihypertensive agents |
US7071210B2 (en) * | 2002-07-02 | 2006-07-04 | Pfizer Inc. | CETP inhibitors in combination with antihypertensive agents and uses thereof |
GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
WO2005097191A2 (en) * | 2004-04-04 | 2005-10-20 | Sepracor Inc. | COMBINATIONS COMPRISING (S)- AMLODIPINE AND A HMG-CoA REDUCTASE INHIBITOR OR CHOLESTEROL ABSORPOTION INHIBITOR OR BOTH, AND METHODS FOR REDUCING HYPERTENSION |
KR100582347B1 (ko) * | 2004-12-30 | 2006-05-22 | 한미약품 주식회사 | 3-하이드록시-3-메틸글루타릴 조효소 a 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법 |
KR100742432B1 (ko) | 2005-12-27 | 2007-07-24 | 한미약품 주식회사 | 암로디핀 캠실레이트 및 심바스타틴을 포함하는 복합제제,및 이의 제조방법 |
CA2645281A1 (en) | 2006-03-29 | 2007-10-04 | Kowa Co., Ltd. | Triglyceride-lowering agent and hyperinsulinism-ameliorating agent |
WO2008023958A1 (en) * | 2006-08-24 | 2008-02-28 | Hanall Pharmaceutical Co., Ltd. | Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors |
WO2008023869A1 (en) * | 2006-08-24 | 2008-02-28 | Hanall Pharmaceutical Co., Ltd. | Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors |
MX2007008440A (es) * | 2007-07-11 | 2009-02-18 | Senosiain S A De C V Lab | Composicion farmaceutica combinada. |
KR20090091084A (ko) * | 2008-02-22 | 2009-08-26 | 한올제약주식회사 | 방출성이 제어된 약제학적 제제 |
WO2009125987A2 (ko) * | 2008-04-10 | 2009-10-15 | 한올제약주식회사 | 약제학적 제제 |
WO2010008203A2 (ko) * | 2008-07-15 | 2010-01-21 | 한올제약주식회사 | 칼슘채널길항제를 포함하는 약제학적 제제 |
CN101804055B (zh) * | 2010-04-27 | 2012-01-25 | 施慧达药业集团(吉林)有限公司 | 复方药物制剂 |
AR103624A1 (es) * | 2015-02-06 | 2017-05-24 | Intercept Pharmaceuticals Inc | Composiciones farmacéuticas para terapia de combinación |
EP3706799A4 (en) * | 2017-11-10 | 2021-08-25 | Op-T Llc | PROCEDURES FOR THE PREVENTION, MODULATION AND / OR REDUCTION OF CARDIOVASCULAR DISEASES |
US11793854B2 (en) | 2019-03-21 | 2023-10-24 | Op-T Llc | Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction |
CN114727955B (zh) * | 2019-11-25 | 2024-03-26 | 福多兹制药公司 | 包含降脂和降血压药物的制剂 |
CN112826937B (zh) * | 2021-03-25 | 2022-03-22 | 山东大学齐鲁医院 | 艾地苯醌与他汀类药物联用在防治动脉粥样硬化中的应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN176897B (ru) * | 1993-10-29 | 1996-09-28 | Cadila Lab Ltd | |
DE19539363A1 (de) * | 1995-10-23 | 1997-04-24 | Basf Ag | Verfahren zur Herstellung von festen Arzneiformen |
-
1998
- 1998-08-10 CA CA002296726A patent/CA2296726C/en not_active Expired - Fee Related
- 1998-08-10 TR TR2000/00562T patent/TR200000562T2/xx unknown
- 1998-08-10 IL IL13395798A patent/IL133957A0/xx unknown
- 1998-08-10 PL PL98339088A patent/PL339088A1/xx unknown
- 1998-08-10 SK SK139-2000A patent/SK1392000A3/sk unknown
- 1998-08-10 NZ NZ502283A patent/NZ502283A/en unknown
- 1998-08-10 AP APAP/P/1998/001333A patent/AP1207A/en active
- 1998-08-10 HN HN1998000124A patent/HN1998000124A/es unknown
- 1998-08-10 JP JP2000508366A patent/JP2001514224A/ja active Pending
- 1998-08-10 EP EP98935246A patent/EP1003507A1/en not_active Withdrawn
- 1998-08-10 BR BR9811558-8A patent/BR9811558A/pt not_active Application Discontinuation
- 1998-08-10 AU AU84585/98A patent/AU744982B2/en not_active Ceased
- 1998-08-10 WO PCT/IB1998/001220 patent/WO1999011263A1/en not_active Application Discontinuation
- 1998-08-10 ID IDW20000199A patent/ID24275A/id unknown
- 1998-08-10 YU YU2700A patent/YU2700A/sh unknown
- 1998-08-10 EA EA200000013A patent/EA002705B1/ru not_active IP Right Cessation
- 1998-08-10 KR KR1020007000964A patent/KR20010022385A/ko not_active Application Discontinuation
- 1998-08-10 HU HU0003103A patent/HUP0003103A3/hu unknown
- 1998-08-10 CN CN98808465A patent/CN1117566C/zh not_active Expired - Fee Related
- 1998-08-11 PA PA19988457201A patent/PA8457201A1/es unknown
- 1998-08-17 GT GT199800134A patent/GT199800134A/es unknown
- 1998-08-19 SA SA98190432A patent/SA98190432A/ar unknown
- 1998-08-24 PE PE1998000768A patent/PE106999A1/es not_active Application Discontinuation
- 1998-08-26 DZ DZ980210A patent/DZ2600A1/xx active
- 1998-08-26 MA MA25231A patent/MA26539A1/fr unknown
- 1998-08-26 TN TNTNSN98158A patent/TNSN98158A1/fr unknown
- 1998-08-27 AR ARP980104289A patent/AR017514A1/es unknown
- 1998-08-27 CO CO98049137A patent/CO4970726A1/es unknown
- 1998-08-27 UY UY25159A patent/UY25159A1/es not_active Application Discontinuation
- 1998-08-28 ZA ZA9807843A patent/ZA987843B/xx unknown
- 1998-08-28 HR HR60/057,555A patent/HRP980475A2/hr not_active Application Discontinuation
-
2000
- 2000-01-09 IL IL133957A patent/IL133957A/en unknown
- 2000-01-13 BG BG104076A patent/BG104076A/xx unknown
- 2000-01-14 IS IS5345A patent/IS5345A/is unknown
- 2000-02-18 OA OA1200000038A patent/OA11289A/en unknown
- 2000-02-28 NO NO20000999A patent/NO20000999D0/no not_active Application Discontinuation
-
2001
- 2001-01-12 HK HK01100323A patent/HK1029530A1/xx not_active IP Right Cessation
- 2001-10-10 US US09/975,765 patent/US20020025981A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200000013A1 (ru) | Комбинационная терапия, включающая в себя амлодипин и статиновое соединение | |
EA200000164A1 (ru) | Терапевтические комбинации, включающие в себя амлодипин и аторвастатин | |
EA200000012A1 (ru) | Комбинационная терапия, включающая в себя аторвастатин и антигипертензивный агент | |
AP2001002347A0 (en) | Mutual salt of amlodipine and atorvastatin. | |
TR200101470T2 (tr) | Farmasötik bileşim terkipleri. | |
UY27402A1 (es) | Composiciones farmacéuticas de amlodipina y atorvastatina | |
PT804229E (pt) | Utilizacao de amlodipina de um dos seus sais ou defelodipina em combinacao com um inibidor da en zima de conversao da angiotensina (ace) para no fabrico de um medicamento destinado ao tratamento da insuficiencia cardiaca congestiva nao isquemica | |
ECSP982645A (es) | Terapia de combinacion | |
ECSP982647A (es) | Terapia de combinacion | |
RU93004718A (ru) | Гетероциклические производные, способ их получения, применение, способ лечения, фармацевтическая композиция | |
ECSP982646A (es) | Combinaciones terapeuticas | |
UY27510A1 (es) | Terapia de combinación |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |